- Home
- LAW vs LYEL Comparison
LAW vs LYEL Comparison
Compare LAW & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LAW | LYEL |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 466.2M | 490.1M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LAW | LYEL |
|---|---|---|
| Price | $4.53 | $21.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $8.00 | ★ $27.25 |
| AVG Volume (30 Days) | ★ 594.3K | 101.0K |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.58 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $156,849,000.00 | $36,000.00 |
| Revenue This Year | $11.23 | N/A |
| Revenue Next Year | $10.60 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.29 | N/A |
| 52 Week Low | $2.45 | $0.39 |
| 52 Week High | $9.11 | $45.00 |
Technical Indicators
Market Signals| Indicator | LAW | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 53.11 | 40.94 |
| Support Level | $3.92 | $21.27 |
| Resistance Level | $4.81 | $27.30 |
| Average True Range (ATR) | 0.38 | 1.81 |
| MACD | 0.20 | -0.10 |
| Stochastic Oscillator | 83.94 | 8.63 |
Price Performance
Historical ComparisonAbout LAW CS Disco Inc.
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.